Document Classification

Section Type: RESULTS

Text: There was no significant difference between age groups randomly assigned to erlotinib or placebo in progression-free survival (elderly : 3. 0 v 2. 1 months ; hazard ratio [HR] = 0. 63 ; 95 % CI, 0. 44 to 0. 90 ; P =. 009 ; young : 2. 1 v 1. 8 months ; HR = 0. 64 ; 95 % CI, 0. 53 to 0. 76 ; P <. 0001 ; interaction, P =. 77) or OS (elderly : 7. 6 v 5. 0 months ; HR = 0. 92 ; 95 % CI, 0. 64 to 1. 34 ; P =. 67 ; young : 6. 4 v 4. 7 months ; HR = 0. 73 ; 95 % CI, 0. 61 to 0. 89 ; P =. 0014 ; interaction, P =. 31).